Physician profile
Ginger Kenney
NPI 1740646777
$1,247.46
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $166 · 2022: $574 · 2023: $358 · 2024: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $507.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $290.70 | 2021-2022 | |
| Abbvie INC. | $274.27 | 2021-2023 | |
| Kowa Pharmaceuticals America, INC. | $131.09 | 2023-2024 | Livalo, Seglentis |
| Almatica Pharma LLC | $113.29 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Otsuka America Pharmaceutical, INC. | $108.65 | 2022 | |
| Alkermes, INC. | $50.49 | 2021-2022 | |
| Lilly USA, LLC | $43.09 | 2023-2024 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $42.95 | 2024 | Trelegy Ellipta |
| Novo Nordisk INC | $42.52 | 2023-2024 | Rybelsus, Ozempic |
| Sunovion Pharmaceuticals INC. | $37.52 | 2022 | |
| Janssen Pharmaceuticals, INC | $23.88 | 2022 | |
| Exact Sciences Corporation | $23.29 | 2023 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $20.93 | 2024 | Airsupra |
| Scilex Pharmaceuticals INC. | $19.19 | 2023 | Ztlido |
| Tris Pharma INC | $13.89 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ginger Kenney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.